Non-curative treatment of patients with oral tongue squamous-cell carcinoma.


Journal

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 24 03 2019
accepted: 27 04 2019
pubmed: 10 5 2019
medline: 6 8 2019
entrez: 10 5 2019
Statut: ppublish

Résumé

Late-stage OTSCC is associated with poor overall survival (OS). Non-curative treatment approach aims to improve quality of life and prolong survival of patients deemed incurable. The purpose of this study was to investigate the used non-curative treatment modalities for OTSSC and patient survival. All patients diagnosed with OTSCC and treated with non-curative intent at the HUS Helsinki University Hospital (Helsinki, Finland) during the 12-year period of 2005-2016 were included. Survival analysis after the non-curative treatment decision was conducted using the Kaplan-Meier method in this population-based study. Eighty-two patients were identified. A non-curative treatment decision was made at presentation without any previous treatment in 26 patients (7% of all patients diagnosed with OTSCC during the study period). Palliative radiotherapy was administered to 24% of all patients. The average survival time after the non-curative treatment decision was 3.7 months (median 2 and range 0-26). Due to the short mean survival time after decision for treatment with non-curative intent, and the notable symptom burden in this patient population, a prompt initiation of all non-curative measures is warranted.

Identifiants

pubmed: 31069467
doi: 10.1007/s00405-019-05456-y
pii: 10.1007/s00405-019-05456-y
pmc: PMC6581924
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2039-2045

Références

Ann Oncol. 2001 Feb;12(2):199-202
pubmed: 11300324
World J Gastroenterol. 2014 Jun 28;20(24):7739-51
pubmed: 24976711
Acta Oncol. 2010 Jun;49(5):561-77
pubmed: 20170293
N Engl J Med. 2007 Oct 25;357(17):1695-704
pubmed: 17960012
Curr Opin Otolaryngol Head Neck Surg. 2014 Apr;22(2):101-8
pubmed: 24419405
Oncologist. 2012;17(2):267-73
pubmed: 22252934
Eur Arch Otorhinolaryngol. 2018 Feb;275(2):545-551
pubmed: 29247265
Oral Oncol. 2015 Oct;51(10):957-62
pubmed: 26282714
Surg Endosc. 2015 Oct;29(10):2941-6
pubmed: 25515981
BMC Palliat Care. 2011 Sep 21;10:14
pubmed: 21936940
Nat Rev Cancer. 2015 Jul;15(7):409-25
pubmed: 26105538
Radiother Oncol. 2018 Mar;126(3):558-567
pubmed: 29370986
Cancer. 2012 Dec 15;118(24):6072-8
pubmed: 22707358
Br J Oral Maxillofac Surg. 2014 May;52(5):458-60
pubmed: 24721168
Front Pharmacol. 2012 Jul 30;3:149
pubmed: 23060791
Cochrane Database Syst Rev. 2011 Apr 13;(4):CD006386
pubmed: 21491393
Head Neck. 2017 Jul;39(7):1306-1312
pubmed: 28481417
J Laryngol Otol. 2016 May;130(S2):S198-S207
pubmed: 27841131
World J Gastroenterol. 2011 Feb 28;17(8):1004-8
pubmed: 21448351
Cancer J. 2010 Sep-Oct;16(5):423-35
pubmed: 20890138
Cancers (Basel). 2017 Jan 24;9(2):
pubmed: 28125017
Eur Arch Otorhinolaryngol. 2007 Mar;264(3):263-7
pubmed: 17021781
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Head Neck. 2011 Jul;33(7):1021-6
pubmed: 20967869
Ther Adv Med Oncol. 2013 Nov;5(6):318-23
pubmed: 24179486
Radiother Oncol. 2015 Nov;117(2):343-50
pubmed: 26508285
J Pain Symptom Manage. 2015 Jun;49(6):1081-1087.e4
pubmed: 25596010

Auteurs

R Mroueh (R)

Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and HUS Helsinki University Hospital, P.O. Box 263, 00029 HUS, FI-00029, Finland.

A Haapaniemi (A)

Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and HUS Helsinki University Hospital, P.O. Box 263, 00029 HUS, FI-00029, Finland.

T Saarto (T)

Department of Oncology, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.

L Grönholm (L)

Department of Oncology, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.

R Grénman (R)

Department of Otorhinolaryngology-Head and Neck Surgery, University of Turku and Turku University Hospital, Turku, Finland.

T Salo (T)

Cancer and Translational Medicine Unit, University of Oulu, Oulu, Finland.
Medical Research Unit, Oulu University Hospital, Oulu, Finland.
Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.
Haartman Institute, Helsinki, Finland.

A A Mäkitie (AA)

Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and HUS Helsinki University Hospital, P.O. Box 263, 00029 HUS, FI-00029, Finland. antti.makitie@helsinki.fi.
Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. antti.makitie@helsinki.fi.
Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden. antti.makitie@helsinki.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH